Introduction
Fear and anxiety are prevalent during childhood and adolescence and thematically vary by age and gender in healthy children and adolescents [1] . However, for 15-20 % of adolescents in the US [2, 3] , this anxiety is associated with significant impairment and crosses the diagnostic threshold of an "anxiety disorder." Thus, anxiety disorders are prevalent among youth and are linked with an increased risk of suicidal ideation and suicide attempts [4] . In addition, fear-based anxiety disorders in youth are associated with significant morbidity [5] , including comorbidity with depressive disorders [6] . Moreover, longitudinal studies suggest that anxiety disorders in childhood are associated with academic impairment and significant interferences in family, school, and social life [7] [8] [9] . Finally, youth with anxiety disorders are at increased risk for secondary anxiety disorders, depressive disorder, nicotine or alcohol dependence, as well as other substance use disorders [8] .
With current knowledge of the prevalence of pediatric anxiety disorders, early intervention is critical to decrease the likelihood of recurrent anxiety and other psychiatric disorders continuing into adulthood. Additionally, studies have shown that youth and adults with anxiety disorders suffer from impairments in quality of life [10, 11] . Consequently, data from multiple studies reveal the advantages of pharmacologic treatment for children and adolescents. Herein, we review recent psychopharmacologic studies of youth with anxiety disorders including generalized anxiety disorder (GAD), social phobia (SoP)/social anxiety disorder, panic disorder (PD), and mixed anxiety disorders. This review is limited to randomized, controlled trials of selective serotonin reuptake inhibitors (SSRIs), selective serotonin norepinephrine reuptake inhibitors (SSNRIs), benzodiazepines, and atypical anxiolytics.
Pediatric GAD Sertraline
& In a 9-week randomized, controlled study, children ages 5-17 (N = 22) diagnosed with GAD were treated with sertraline (n = 11) or placebo (n = 11) [12] . & Sertraline was initiated at 25 mg/day during the first week and then dosed at 50 mg/day from week 2 to 9. & Hamilton Anxiety Scale for Anxiety (HAM-A) scores and the Clinical Global Impression (CGI) severity and improvement scale scores showed significant improvement in sertraline-treated patients, compared to those receiving placebo. & Adverse events included dry mouth, drowsiness, leg spasms, and restlessness.
Fluoxetine
& In a 12-week randomized, controlled study of anxious youth (aged 7-17 years), fluoxetine (n = 24) decreased anxiety compared to a placebo (n = 22) [13] . & Fluoxetine was initiated at 10 mg daily and titrated to a maximum dosage of 20 mg daily. & Sixty-seven percent of fluoxetine patients (compared to 36 % of those receiving placebo), had CGI-I scores ≤2. & Common side effects included nausea, abdominal pain, headaches, and drowsiness. & Patients receiving paroxetine exhibited a greater response rate (CGI-I 77.6 % of the paroxetine-treated vs. 33.8 % of placebo-treated patients, p G 0.001) and, in this sample, paroxetine was well tolerated. & However, decreased appetite, vomiting, and insomnia were observed among the sample. Four paroxetine-treated patients (compared to zero placebotreated patients) experienced emotional lability and suicidal ideation.
Tandospirone
& The 5-HT 1A receptor partial agonist, tandospirone, which is commonly utilized anxiolytic in Asia, has been evaluated in an 8-week open-label parallel controlled trial in youth with social anxiety disorder (N = 71) ages 14-21 [18] . & Tandospirone was flexibly dosed and titrated to 20-60 mg/day. An active comparator, sertraline, was initiated at 25 mg for 1 week and then titrated to a maximum of 200 mg/day. & 48.6 % of tandospirone-treated patients was improved in terms of CGI-I scores compared to 55.6 % of patients receiving sertraline. HAM-A scores significantly improved in both treatment groups (p G 0.0001). Social Phobia Inventory scores also showed significant improvements over baseline in both treatments (p G 0.0001). These pilot studies raise the possibility that tandospirone is not inferior to sertraline in the treatment for SAD in youth. However, it is of interest that buspirone, also a 5-HT 1A partial agonist did not differ from placebo in terms of anxiety-related symptoms in pediatric patients with GAD (GSK, 2015). & The most common adverse events for tandospirone were drowsiness, fatigue, and decreased appetite [18] .
Clonazepam
& In a double-blind, placebo cross-over trial, the benzodiazepine, clonazepam, decreased anxiety symptoms in youth with social anxiety disorder and/or GAD (aged 7-13 years, N = 15), but no differences were detected between placebo and clonazepam in terms of CGI-I scores. Side effects included drowsiness, irritability, as well as oppositional behavior which occurred more frequently during clonazepam treatment [24] .
Mixed Anxiety Disorders
Sertraline & The Child/Adolescent Anxiety Multimodal Study (CAMS) was a 12-week randomized, controlled study with youth patients ages 7-17 (N = 488) diagnosed with separation anxiety disorder, GAD, and/or social anxiety disorder [12] . & Patients were randomized to: sertraline (n = 133), cognitive behavioral therapy (n = 139), combination therapy (n = 140), or placebo (n = 76). & Sertraline was initiated at 25 mg/day and titrated to a maximum dose of 200 mg/day. More than half of sertraline patients (54.9 %) exhibited improvement based on CGI-I scores while 80.7 % of youth treated with cognitive based therapy (CBT) + sertraline met response criteria for (p G 0.001) compared to 59.7 % in patients receiving CBT (p G 0.001). All active treatments were statistically superior to placebo [12, 19] . & Adverse events including suicidality did not occur more frequently inpatients receiving placebo compared to those who were treated with sertraline. Additionally, there were no statistically significant differences between sertralinetreated patients and those who received placebo in terms of headaches, gastrointestinal symptoms or insomnia [12] .
Fluvoxamine & An 8-week randomized, controlled trial of children, ages 6-17 (N = 128), who met criteria for social anxiety disorder, separation anxiety disorder, or generalized anxiety disorder examined the efficacy of fluvoxamine. In this study, fluvoxamine was titrated by 50 mg each week to a maximum of 300 mg/day for adolescents and 250 mg/day for children G12 years of age [20] . & The fluvoxamine-treated patients exhibited a 76 % improvement based on CGI-I scores compared to only 29 % of the placebo group (p G 0.001).
Additionally, cumulative response rates on the CGI-I scores significantly increased over time raising the possibility that an adequate fluvoxamine trial may be 96 weeks. & Abdominal discomfort and increased motor activity were the two statistically significant adverse events [20] . Although, it is noteworthy that fluvoxamine was associated with a reduction in somatic symptoms in [21] . the CGI-I scale compared to 35% of the placebo group (n = 37) [13] . & Side effects included abdominal pain, nausea, drowsiness, and headaches [13] . & A 9-week open-label pilot study involving 16 patients (ages 9-18) with mixed anxiety disorders examined the efficacy of fluoxetine. In this study, fluoxetine was initiated at 5 mg/day and then increased weekly, with a maximum of 40 mg for children less than 12 years, and 80 mg for adolescents [22] . & Fluoxetine-treated youth exhibited clinically significant improvement with regard to CGAS and CGI-S scores [22] . & The most common side effects included drowsiness, insomnia, decreased appetite, nausea, abdominal pain, and being easily excited [22] Alprazolam & In a double-blind, placebo-controlled study of youth with GAD, (mean age 12.6 years, N = 30), alprazolam did not result in statistically significant improvement compared to placebo in terms of global improvement [23] .
& Side effects of benzodiazepines in youth include irritability, drowsiness, and "oppositional behavior" [24] as well as dry mouth and sedation [23] .
Guanfacine (Extended Release)
& A recent double-blind, placebo controlled was completed in which 83 patients with GAD, SAD and/or social anxiety disorder were randomized 3:1 to an extended release formulation of the α 2A receptor agonist guanfacine (GXR) [25] . & Adverse events including headache, somnolence/fatigue, abdominal pain, and dizziness, were consistent with the known side-effect profile of GXR; treatment-emergent suicidality did not differ between groups [25] . & At endpoint/early termination, improvement in PARS score was observed in both groups and 6 (31.6 %) and 32 (54.2 %) patients on placebo and GXR, respectively, had CGI-I scores ≤ 2. However, the study was not powered to detect efficacy [25] .
Pediatric Panic Disorder
Paroxetine & A chart review of child and adolescent patients with panic disorder (N = 18) examined the effectiveness and safety of paroxetine. Treatment duration was variable [26] . & The mean initial dosage was 8.9 mg/day, and the maximum dosage was 40 mg day. & 83.3 % of the patients responded in terms of CGI-S score (baseline-toendpoint p G 0.0001). & Side effects included nausea, tension, headache, sedation, insomnia, agitation, palpitations, and diarrhea. & Paroxetine was tolerated in this retrospective sample [26] , although subsequent prospective studies of this medication in anxious youth have raised concerns related to tolerability and safety [27] .
Pharmacologic Treatment of Anxiety Disorders in Adolescents
Current data suggest improved outcomes with psychotherapy in pediatric anxiety disorders and, while there are no randomized clinical trials related to a severity-based treatment algorithm, expert opinion and American Academy of Child and Adolescent Psychiatry Practice Parameters [28, 29] suggest that pharmacotherapy might be reserved for patients with moderate to severe anxiety (Fig. 1a) . In such cases, an SSRI is considered a first-line psychopharmacologic intervention, although a switch to another SSRI or SSNRIs may be considered for patients who have persistent anxiety symptoms despite titration of the SSRI and optimization of psychotherapy (Fig. 1a) . Additionally, there has been considerable discussion with regard to the cross-titration of antidepressants in pediatric patients with anxiety disorders. Two approaches are generally utilized in clinical practice, although there is debate related to the "overlap" of the two medications. While starting the second medication after the withdrawal of the first medication (Fig. 1b) may be advantageous in situations wherein there are significant side effects, this may result in a rapid loss of the any anxiolytic benefit, if any benefit had been conferred by the first antidepressant. By contrast, titrating the second antidepressant while maintaining the first antidepressant dose represents a second approach (Fig. 1c) . In general, and in the absence of significant side effects or when partial response is present, an overlap in administration of the two medications is preferred as illustrated in Fig. 1c .
Predictors of Pharmacologic Treatment Response in Pediatric Patients with Anxiety
& Demographic factors including male sex, non-minority status, and better family functioning predict improved treatment response in Fig. 1 . Treatment algorithm for pediatric anxiety disorders. In a, blue boxes represent pharmacological interventions. Beneath each intervention is a "Response" box that suggests other options if a certain treatment is associated with partial, or no improvement. Additionally, two cross-titration strategies for antidepressants are illustrated in b and c. SSRI selective serotonin reuptake inhibitor, SSNRI selective serotonin norepinephrine reuptake inhibitor pediatric anxiety disorders. Additionally, being older, having a firstdegree relative with an anxiety disorder also predict poorer outcomes [12, 13, 30, 31] . & Importantly, specific anxiety disorders and comorbidities influence treatment response and remission and in this regard, a primary diagnosis of social anxiety disorder is associated with poorer treatment responses and remission rates [13, 30, 32 •], with one study noting pharmacotherapy (e.g., sertraline) as a requisite for any response, even when CBT is present. & Comorbid internalizing disorders with a pediatric triad anxiety disorder decrease the likelihood of remission [30] . & Several studies reveal anxiety severity to be an important predictor of treatment outcome, with more anxiety, at baseline, being associated with poorer outcomes [13, 30, 32•, 33] .
Conclusions
Accumulating data suggest that antidepressants-including SSRIs and SSNRIs are effective for the treatment of pediatric patients with anxiety disorders and are well tolerated [29, 34••, 35] . Though, the salutary effects of SSRIs and SSNRIs in pediatric anxiety disorders are consistently amplified by the addition of psychotherapy, particularly in individuals with social anxiety disorder. Thus, current data and practice parameters from the American Academy of Child and Adolescent Psychiatry recommend multimodal treatments for youth with GAD, social anxiety disorder, and separation anxiety disorders. However, treatment approaches are constantly evolving and definitive answers related to treatment duration, the role of adjunctive treatments in partial responders, and the potential utility of pharmacogenomic testing is urgently needed.
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